Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.47 |
| ▸ | RELA | Q04206 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | SNCA | P37840 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7975064 | 0.86 | SMN1; SMN2 (0.59) | NPC1RAB9ASMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL17646417 | 0.83 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL28243327 | 0.83 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL17646245 | 0.81 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL7032673 | 0.80 | ALOX15 (0.46) | NPC1RAB9ASMN1; SMN2HPGDL3MBTL1 | |
| Hydrochloric Acid SCHEMBL17646325 | 0.80 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL28341579 | 0.80 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2HPGDL3MBTL1 | |
| Hydrochloric Acid SCHEMBL17646398 | 0.80 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL4945628 | 0.79 | CSNK1D (0.60) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL30100560 | 0.78 | ALOX15 (0.55) | NPC1RAB9ASMN1; SMN2HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730671-B2 | ENZYME INHIBITOR TREATING AUTOIMMUNE DISEASES, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | disclosed |
| US-20030158406-A1 | Compounds useful as reversible inhibitors of cathepsin S | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | disclosed |
| US-6608057-B2 | Compounds useful as reversible inhibitors of cathepsin S | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-19 | — | — | US | disclosed |
| US-20020091259-A1 | Compounds useful as reversible inhibitors of cathepsin S | CYWIN CHARLES L (US) | 2002-07-11 | — | — | US | disclosed |
| US-6395897-B1 | DRUGS FOR ENZYME INHIBITORS ANTICOAGULANTS AND TREATMENT OF AUTOIMMUNE DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-05-28 | — | — | US | disclosed |
| EP-1159273-A1 | COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CATHEPSIN S | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000051998-A1 | COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CATHEPSIN S | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091259-A1 | Compounds useful as reversible inhibitors of cathepsin S | CTSS, CTSB, CTSV | NPC1 239/4885RAB9A 256/4885SMN1; SMN2 4257/4885 |
| US-20030158406-A1 | Compounds useful as reversible inhibitors of cathepsin S | CTSS, CTSB, CTSV | NPC1 239/4885RAB9A 256/4885SMN1; SMN2 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.